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was the traditional standard of care, but agreed that 
chemoradiation was a reasonable alternative because 
cystectomy could be reserved for salvage.
Clinical examination revealed no significant 
physical findings, and the patient denied further he-
maturia, increased urinary frequency, urinary urgency, 
urinary retention, dysuria, incontinence, anorexia, or 
weight loss. She denied ever smoking, but reported a 
significant history of second-hand exposure. Her past 
medical history was significant for a peptic ulcer, and 
her past surgical history included appendectomy and 
tonsillectomy.
We developed a treatment program consisting of 
7 weeks of weekday radiation therapy integrated with 
chemotherapy, with follow-up routine cystoscopy 
thereafter to monitor response. The patient’s radiation 
program consisted of 36 fractions over 49 days, with 
a dose of 39.6 Gy to the bladder and pelvic lymph 
nodes followed by 25.2 Gy to the bladder tumour. Her 
chemotherapy regimen consisted of cisplatin 35 mg/
m2 (49 mg in 500 mL normal saline over 1 hour) at 
the beginning of weeks 1, 3, 5, and 7, with each cycle 
divided over 2 consecutive days. She was also treated
 
f i g u r e  1 Invasive high-grade urothelial carcinoma (arrow) with 
prominent sarcomatoid and neuroendocrine elements.
ABSTRACT
The standard treatment for locally advanced urothelial 
bladder carcinoma is radical cystectomy or chemo-
radiation. Sarcomatoid urothelial carcinoma, a rare 
tumour, is treated with radical cystectomy because the 
response to radiation therapy alone is poor in other 
sarcomas. We report a case of high-grade hyperinva-
sive urothelial bladder carcinoma with sarcomatoid 
differentiation. The patient refused cystectomy, and 
so a chemoradiation regimen was devised for her 
treatment. She completed the regimen and has since 
demonstrated a complete response to chemoradiation 
therapy clinically and pathologically by biopsy. The 
patient has therefore been able to attain a complete 
response while preserving a functional bladder.
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1.  CASE DESCRIPTION
Presentation of a 67-year-old white woman who had 
experienced several weeks of hematuria with clots 
led to consultations at two outside hospitals (o s h s). 
Cystoscopy and transurethral resection at the first o s h  
revealed a high-grade urothelial bladder carcinoma 
with areas of sarcomatoid and neuroendocrine dif-
ferentiation. The patient was advised to have radical 
cystectomy. A repeat biopsy at the second o s h  re-
vealed invasive high-grade urothelial carcinoma with 
prominent sarcomatoid and neuroendocrine elements, 
and invasion of the muscularis propria, classified as 
T2AN0 stage ii (Figure 1). The patient was further 
advised that bladder-conserving approaches were not 
recommended because of the likely poor response to 
chemoradiation by the sarcomatoid elements, render-
ing radical cystectomy the standard of care. However, 
the woman continued to seek bladder preservation and 
presented to our institution to discuss bladder-sparing 
options. We also advised her that radical cystectomy WALLACH et al.
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with palonosetron HCl 0.25 mg intravenous (IV) 
bolus and dexamethasone 20 mg IV in 50 mL normal 
saline while receiving chemotherapy.
The patient tolerated therapy well, without inter-
ruptions and with only mild diarrhea that improved 
with loperamide. Cystoscopy was performed 2.5 
months after chemoradiation and revealed no cancer-
ous lesions. Biopsies taken from the initial tumour 
location at that time were negative for carcinoma 
(Figure 2).
2.  DISCUSSION AND CONCLUSIONS
Bladder cancer is the most common urinary tract 
malignancy, with 67,160 new cases and 13,750 deaths 
occurring each year in the United States 1. The 3:1 
male predominance is believed to be a result of higher 
smoking rates and greater exposure to occupational 
poisons among men, although some researchers pos-
tulate that the more-active androgen receptor in men 
accelerates carcinogenesis 2–4. Overall, the 5-year 
survival rate is 82% 1.
In North America and Europe, simple urothelial 
carcinomas account for more than 90% of bladder 
malignancies, with epithelial tumours constituting 
an additional 9% 5,6. The treatment protocol depends 
on the depth of invasion, which is categorized as 
superficial, muscle-invasive, or hyperinvasive. Su-
perficial malignancies may be treated with electro-
cautery or instillation of bacille Calmette–Guérin; 
hyperinvasive tumours necessitate radical cystectomy 
with chemoradiation. For muscle-invasive tumours, 
radical cystectomy with or without chemotherapy 
has been the traditional standard, but in an effort to 
improve quality of life by avoiding urinary diversion 
procedures, the bladder-sparing trimodality therapy 
of transurethral resection of bladder tumour, systemic 
chemotherapy, and concurrent radiation therapy has 
increasingly been used in selected patients. Several 
studies have concluded that this approach has a 5-year 
survival for muscle-invasive tumours comparable to 
that for radical cystectomy in patients of similar age 
and stage (generally 40%–60%) 7–10.
Sarcomatoid carcinomas of the bladder are ex-
ceedingly rare and highly aggressive spindle-cell 
neoplasms that are usually diagnosed at an advanced 
stage and have a median survival of 10 months 7,11. 
Radical surgery with adjuvant radiation therapy 
to eradicate microscopic disease is the traditional 
standard treatment for most sarcomas, because these 
tumours show poor response to primary radiation 
therapy 7. Literature for nonsurgical therapy for these 
bladder tumours is scarce. One case report describes 
a patient with metastatic sarcomatoid bladder carci-
noma who demonstrated a clinical complete remission 
after cisplatin and gemcitabine, and another describes 
a complete remission after neoadjuvant chemotherapy 
using carboplatin and gemcitabine followed by partial 
cystectomy 12,13. Our report demonstrates only 1 case 
with limited follow-up, but the favourable tumour 
response, coupled with an improved quality of life 
with a native bladder, provides a strong argument for 
bladder-preserving chemoradiation as an alternative 
treatment regimen.
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